Canada's GLP research peptide line — single, dual, and triple incretin agonists at 99%+ HPLC purity, third-party tested every lot, with flat $30 Xpresspost shipping nationwide.
Section 01 — The class
GLP-1 research peptides are a class of incretin receptor agonists studied for their effects on metabolic signalling. The class has moved quickly — from single GLP-1 agonists, to dual agonists that add a second receptor, to triple agonists that engage three. Most searches for "GLP-1 research peptides" or a "GLP-3 peptide" are really about where a compound sits on that spectrum.
Single GLP-1 agonists act on the glucagon-like peptide-1 receptor alone. Semaglutide is the best-known example of this generation, which is why it is the reference point most researchers start from when comparing newer compounds.
Dual agonists add a second incretin receptor. Tirzepatide is the canonical dual agonist, acting on both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. Engaging two pathways at once is the structural reason it is studied separately from single-agonist compounds.
Triple agonists add a third. Retatrutide acts on GLP-1, GIP, and glucagon receptors simultaneously — three mechanisms in one molecule. That third receptor is why retatrutide is sometimes described informally as a "GLP-3" peptide, even though that is a colloquial label rather than a formal classification.
The shorthand is simple: tirzepatide hits two receptors, retatrutide hits three. The "GLP-3" you see in search queries is researchers reaching for a name for the triple-agonist generation.
Helix North also stocks cagrilintide, a long-acting amylin analog frequently studied alongside the incretin agonists rather than as a GLP-1 compound itself. We supply every compound on this page strictly as a research material for in-vitro and laboratory use, with no dosing, protocol, or clinical guidance attached.
Section 02 — Evidence
Purity matters more, not less, for GLP peptides. Retatrutide and tirzepatide are longer, more complex sequences than most research peptides, which means more opportunities for truncated or deamidated synthesis byproducts. The phrase "99% pure" is meaningless without a chromatogram, a lot number, and a lab signature attached to it. Our position is that if a number is going to appear on a product page, it has to be tied to a verifiable test.
Every production lot is screened on two axes: identity and purity. Identity is verified by LC-MS, which measures the molecular mass of the compound and confirms it matches the peptide's theoretical mass within a tolerance of less than half a Dalton. Purity is measured by HPLC, which separates the sample on a reverse-phase column and quantifies the target-peak area against everything else in the chromatogram.
The HPLC and LC-MS work is performed by an independent third-party laboratory that has no financial relationship with our sales. They run the assay, generate the chromatogram, and report the result. We pass or fail the lot on that report. We do not adjust the number, round it, or republish it — the PDF the lab returns is the PDF we publish on the product page.
HPLC catches synthesis impurities, truncated sequences, residual solvents, and deamidation products. LC-MS catches identity mismatches — cases where the synthesis produced a similar but wrong peptide. Together they cover the two most common failure modes for peptide manufacturing. Lots that fail either test do not enter the catalog.
For the long-form on our methodology, equipment, and the independent lab we work with, see our quality page. Every product page links to the Certificate of Analysis PDF for that specific lot. The lot number on the vial label maps to the CoA on file.
Section 03 — From the catalog
Our GLP-1 and GLP-3 research line — retatrutide, tirzepatide, and cagrilintide, in multiple vial sizes. Every product ships with a Certificate of Analysis from the third-party lab that tested its lot. See the full range on the shop page.
Section 04 — Comparison
The most common GLP question we get is how retatrutide and tirzepatide differ. The short answer is receptor count: tirzepatide is a dual agonist, retatrutide is a triple agonist. The longer answer is what that third receptor changes about how each compound is studied. What follows is structural and mechanistic context for research, not dosing or clinical guidance.
Tirzepatide engages the GLP-1 and GIP receptors. The dual-incretin design is the reason it became a distinct research subject rather than another single-agonist analog — activating GIP alongside GLP-1 produces signalling that single agonists do not. It is the more established of the two, with a deeper body of published work behind it.
Retatrutide adds the glucagon receptor to those two. The glucagon arm is the differentiator and the reason retatrutide is studied separately from dual agonists — triple engagement is mechanistically distinct, and it is the newest generation of the class. This is the compound behind most "GLP-3 peptide" searches.
Tirzepatide is the established dual agonist; retatrutide is the newer triple agonist. Which one a lab sources depends on which receptor profile its protocol calls for.
Cagrilintide is a different mechanism entirely — a long-acting amylin analog, not an incretin agonist. It appears in this line because it is frequently studied in combination with GLP compounds, but it is not a GLP-1, dual, or triple agonist itself.
All three are supplied as lyophilized vials with a per-lot third-party Certificate of Analysis. For handling, our retatrutide reconstitution guide covers the calculation and procedure for research use. We do not publish dosing, protocols, or clinical recommendations for any GLP compound.
Section 05 — Logistics
Every GLP peptide order ships via Canada Post Xpresspost with tracking, in plain unmarked ambient-temperature packaging, for a flat $30 CAD regardless of cart size, anywhere in the country — and because it never leaves Canada, there is no customs clearance to wait on.
Xpresspost is Canada Post's expedited service. It delivers to every postal code in Canada including PO boxes, rural routes, and northern territories. Tracking is included. Signature confirmation is available on request. From our Ontario shipping origin, typical transit ranges from 1–2 business days for central Canada to 3–7 days for northern and remote codes.
Lyophilized research peptides are stable at ambient temperatures for the duration of an Xpresspost transit. The published stability data for these compounds supports this. We ship in plain packaging without cold packs or insulated liners, because they add weight, cost, and visual signature without measurably improving the product on arrival. If your research specifically requires cold-chain shipping for a non-standard compound, contact us before ordering and we will discuss options.
| Region | Typical postal codes | Transit |
|---|---|---|
| Central | ON, QC | 1–2 business days |
| Atlantic | NB, NS, PE, NL | 2–3 business days |
| Prairies | MB, SK, AB | 2–3 business days |
| West Coast | BC | 2–4 business days |
| Northern | YT, NT, NU | 3–7 business days |
Packaging is plain and unmarked. No external branding identifies the package contents. The return address is a generic Canadian business address. Discretion is not a marketing claim — it is how the package actually looks when it arrives.
Section 06 — Common questions
Browse retatrutide, tirzepatide, and cagrilintide, or get in touch with questions about lot availability, bulk pricing, or a compound not yet in the catalog.